[go: up one dir, main page]

GB9019812D0 - Novel antibodies for treatment and prevention of infection in animals and man - Google Patents

Novel antibodies for treatment and prevention of infection in animals and man

Info

Publication number
GB9019812D0
GB9019812D0 GB909019812A GB9019812A GB9019812D0 GB 9019812 D0 GB9019812 D0 GB 9019812D0 GB 909019812 A GB909019812 A GB 909019812A GB 9019812 A GB9019812 A GB 9019812A GB 9019812 D0 GB9019812 D0 GB 9019812D0
Authority
GB
United Kingdom
Prior art keywords
infection
man
animals
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB909019812A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCOTGEN Ltd
Original Assignee
SCOTGEN Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCOTGEN Ltd filed Critical SCOTGEN Ltd
Priority to GB909019812A priority Critical patent/GB9019812D0/en
Publication of GB9019812D0 publication Critical patent/GB9019812D0/en
Priority to IE317791A priority patent/IE913177A1/en
Priority to ZA917170A priority patent/ZA917170B/en
Priority to NZ250415A priority patent/NZ250415A/en
Priority to NZ239728A priority patent/NZ239728A/en
Priority to EP19910916461 priority patent/EP0548190A1/en
Priority to JP3514980A priority patent/JPH06501152A/en
Priority to PT98944A priority patent/PT98944B/en
Priority to CA002091335A priority patent/CA2091335A1/en
Priority to AU85058/91A priority patent/AU654827B2/en
Priority to MX9101046A priority patent/MX9101046A/en
Priority to PCT/GB1991/001554 priority patent/WO1992004381A1/en
Priority to KR1019930700750A priority patent/KR930702519A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GB909019812A 1990-09-11 1990-09-11 Novel antibodies for treatment and prevention of infection in animals and man Pending GB9019812D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GB909019812A GB9019812D0 (en) 1990-09-11 1990-09-11 Novel antibodies for treatment and prevention of infection in animals and man
IE317791A IE913177A1 (en) 1990-09-11 1991-09-10 Novel antibodies for treatment and prevention of infection¹in animals and man
ZA917170A ZA917170B (en) 1990-09-11 1991-09-10 Novel antibodies for treatment and prevention of infection in animals and man
NZ250415A NZ250415A (en) 1990-09-11 1991-09-10 Monoclonal antibody directed against rsv epitope 417-438, its use and production
NZ239728A NZ239728A (en) 1990-09-11 1991-09-10 Altered antibodies containing parts from donor monoclonal antibodies with specificity for respiratory virus
PCT/GB1991/001554 WO1992004381A1 (en) 1990-09-11 1991-09-11 Novel antibodies for treatment and prevention of infection in animals and man
JP3514980A JPH06501152A (en) 1990-09-11 1991-09-11 Novel antibodies for the treatment and prevention of infections in animals and humans
EP19910916461 EP0548190A1 (en) 1990-09-11 1991-09-11 Novel antibodies for treatment and prevention of infection in animals and man
PT98944A PT98944B (en) 1990-09-11 1991-09-11 PROCESS FOR THE PREPARATION OF ALTERED ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFECTIONS
CA002091335A CA2091335A1 (en) 1990-09-11 1991-09-11 Antibodies for treatment and prevention of infection in animals and man
AU85058/91A AU654827B2 (en) 1990-09-11 1991-09-11 Novel antibodies for treatment and prevention of infection in animals and man
MX9101046A MX9101046A (en) 1990-09-11 1991-09-11 NOVEL ANTIBODIES FOR THE TREATMENT AND PREVENTION OF INFECTION OF ANIMALS AND MAN
KR1019930700750A KR930702519A (en) 1990-09-11 1993-03-11 Novel antibodies to treat and prevent infections in animals and humans

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909019812A GB9019812D0 (en) 1990-09-11 1990-09-11 Novel antibodies for treatment and prevention of infection in animals and man

Publications (1)

Publication Number Publication Date
GB9019812D0 true GB9019812D0 (en) 1990-10-24

Family

ID=10682003

Family Applications (1)

Application Number Title Priority Date Filing Date
GB909019812A Pending GB9019812D0 (en) 1990-09-11 1990-09-11 Novel antibodies for treatment and prevention of infection in animals and man

Country Status (12)

Country Link
EP (1) EP0548190A1 (en)
JP (1) JPH06501152A (en)
KR (1) KR930702519A (en)
AU (1) AU654827B2 (en)
CA (1) CA2091335A1 (en)
GB (1) GB9019812D0 (en)
IE (1) IE913177A1 (en)
MX (1) MX9101046A (en)
NZ (1) NZ239728A (en)
PT (1) PT98944B (en)
WO (1) WO1992004381A1 (en)
ZA (1) ZA917170B (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69130708T2 (en) * 1990-07-19 1999-05-27 The United States Of America As Represented By The Secretary, United States Department Of Commerce, Springfield, Va. IMPROVED IMMUNOTHERAPEUTIC METHOD FOR PREVENTING OR TREATING VIRAL DISEASES OF THE respiratory tract
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
DE69233367T2 (en) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla LIBRARIES OF HETERODIMERIC RECEPTORS BY PHAGEMIDES
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5646253A (en) * 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
US6685942B1 (en) 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
JP3976333B2 (en) * 1992-09-16 2007-09-19 ザ スクリップス リサーチ インスティチュート Human neutralizing monoclonal antibody against respiratory syncytial virus
AU688751B2 (en) 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
CN1132516A (en) * 1993-07-30 1996-10-02 奥拉维克斯公司 Monoclonal IgA antibody against respiratory syncytial virus
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
WO1995031546A1 (en) * 1994-04-28 1995-11-23 Scotgen Biopharmaceuticals, Inc. Recombinant human anti-varicella zoster virus antibodies
CA2230127A1 (en) * 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
EP0909277B2 (en) 1996-06-07 2008-12-24 Poniard Pharmaceuticals, Inc. Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
PT970206E (en) 1997-01-27 2008-10-28 Ludwig Inst Cancer Res Lage-1 tumor associated nucleic acids
EP2305235A1 (en) 1997-04-02 2011-04-06 The Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
AU776672B2 (en) 1998-12-30 2004-09-16 Beth Israel Deaconess Medical Center Characterization of a calcium channel family
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
WO2001000874A2 (en) 1999-06-30 2001-01-04 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
DE60044904D1 (en) 1999-09-03 2010-10-14 Brigham & Womens Hospital METHOD AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES USING CADHERINE-11 MODULATING AGENTS
JP2003512057A (en) 1999-10-19 2003-04-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ MAGE-A12 antigen peptide and use thereof
SK8612002A3 (en) * 1999-12-23 2003-03-04 Ribapharm Inc Compositions and methods for L-nucleosides, L-nucleotides, and their analogs
JP2003535907A (en) 2000-06-22 2003-12-02 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Method for promoting antibody-induced cell lysis and treating cancer
DE10211088A1 (en) 2002-03-13 2003-09-25 Ugur Sahin Gene products differentially expressed in tumors and their use
DK3072978T3 (en) 2002-05-09 2018-09-17 Brigham & Womens Hospital Inc : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
HUE027210T2 (en) 2003-02-11 2016-10-28 Shire Human Genetic Therapies Cells that coexpress a sulfatase and a C-formylglycine generating enzyme and methods and uses thereof
WO2005077344A2 (en) 2003-08-29 2005-08-25 The Brigham And Women's Hospital, Inc. Hydantoin derivatives as inhibitors of cellular necrosis
DE10341812A1 (en) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
DE10344799A1 (en) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
DE102004023187A1 (en) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
US9164104B2 (en) 2004-10-06 2015-10-20 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
DE102005013846A1 (en) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1795596A1 (en) 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
DE102005059242A1 (en) 2005-12-12 2007-06-14 Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten Molecular markers for tumor diagnosis and therapy
WO2007119774A1 (en) 2006-04-13 2007-10-25 Chugai Seiyaku Kabushiki Kaisha Taurine transporter gene
EP1911851A1 (en) 2006-10-12 2008-04-16 Ganymed Pharmaceuticals AG Compositions and methods for therapy and diagnosis of cancer and cancer metastasis
WO2008103845A2 (en) 2007-02-23 2008-08-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services. Monoclonal antibodies that neutralize anthrax toxins
EP2135946B1 (en) 2007-03-15 2015-12-09 Chugai Seiyaku Kabushiki Kaisha Method for production of polypeptide
EP2186905B1 (en) 2007-08-07 2016-07-13 Chugai Seiyaku Kabushiki Kaisha Method of producing heterogeneous protein
JP5337043B2 (en) 2007-10-15 2013-11-06 中外製薬株式会社 Method for producing cells producing high production of heterologous protein
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
MX2010004397A (en) * 2007-10-24 2010-06-01 Chugai Pharmaceutical Co Ltd Cell for use in the production of exogenous protein, and production process using the cell.
EP2108701A1 (en) 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
MX2011000891A (en) * 2008-07-21 2011-06-01 Immunomedics Inc Structural variants of antibodies for improved therapeutic characteristics.
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
EP2398902B1 (en) 2009-02-20 2023-10-04 Astellas Pharma Inc. Methods and compositions for diagnosis and treatment of cancer
EP2221375A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
EP2423309B1 (en) 2009-04-22 2018-01-03 Chugai Seiyaku Kabushiki Kaisha A method for producing a cell capable of high-yield production of heteroproteins
EP2249159A1 (en) 2009-04-29 2010-11-10 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
NO2499161T3 (en) 2009-11-11 2018-02-03
MX340683B (en) 2010-04-16 2016-07-21 Biogen Ma Inc Anti-vla-4 antibodies.
WO2011133894A2 (en) 2010-04-23 2011-10-27 Purdue Research Foundation Protein drug formulations and packages
JP5911848B2 (en) 2010-05-04 2016-04-27 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド Fibrosis detection and treatment
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
HUE028603T2 (en) 2011-05-13 2016-12-28 Ganymed Pharmaceuticals Ag Antibody for treating cancers expressing claudin-6
US20140322723A1 (en) 2011-11-22 2014-10-30 President and Dellows of Harvard College Diabetes diagnosis through the detection of glycated proteins in urine
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
RU2016134256A (en) 2014-01-24 2018-03-05 Дзе Генри М. Джексон Фаундейшн Фор Дзе Эдвансмент Оф Милитари Медсин, Инк. ANTIBODIES AGAINST HANDRA VIRUSES AND NICA F Glycoprotein
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
JO3555B1 (en) 2015-10-29 2020-07-05 Merck Sharp & Dohme Antibody neutralizing human respiratory syncytial virus
WO2017147258A1 (en) 2016-02-23 2017-08-31 Indiana University Research & Technology Corporation Emapii neutralizing antibody limits influenza a virus (iav)-induced lung injury
WO2017213695A1 (en) 2016-06-07 2017-12-14 The Brigham And Women's Hospital, Inc. Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions
WO2019025299A1 (en) 2017-07-31 2019-02-07 F. Hoffmann-La Roche Ag Three-dimensional structure-based humanization method
JP7457661B2 (en) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド Anti-VLA-4 antibodies with reduced effector function

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb

Also Published As

Publication number Publication date
PT98944A (en) 1992-08-31
IE913177A1 (en) 1992-03-11
ZA917170B (en) 1992-07-29
NZ239728A (en) 1995-07-26
JPH06501152A (en) 1994-02-10
EP0548190A1 (en) 1993-06-30
KR930702519A (en) 1993-09-09
WO1992004381A1 (en) 1992-03-19
AU8505891A (en) 1992-03-30
AU654827B2 (en) 1994-11-24
CA2091335A1 (en) 1992-03-12
PT98944B (en) 1999-02-26
MX9101046A (en) 1992-05-04

Similar Documents

Publication Publication Date Title
ZA917170B (en) Novel antibodies for treatment and prevention of infection in animals and man
GB9207479D0 (en) Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
SG49658A1 (en) Treatment of condition and disease
GB9014307D0 (en) Method of treatment and compositions therefor
GB9203206D0 (en) Treatment of particulate material
GB2255506A (en) Drug for preventing and treating fish diseases
ZA914435B (en) Treatment of disease
FR2663230B1 (en) HYGIENE AND TREATMENT DEVICE.
GB2263905B (en) Treatment of waste animal materials
EP0527771A4 (en) Polypeptides useful in diagnosis of and treatment against mycoplasma infections in animals
EP0540575A4 (en) Human meg-csf protein and methods
IL101749A0 (en) Treatment of mastitis
CS61691A2 (en) Composition for dung-water treatment and method of dung-water treatment
GB9216360D0 (en) Treatment of blood
KR960006863B1 (en) Pharmaceutical preparation for treatment of mastitis in animals and humans
EG20171A (en) Treatment of conditions and disease
ZA914464B (en) Method and compositions for treating hiv-type 1 infection
AU2492892A (en) The device for treatment and prophylaxis of mastitis in animals
GB2245475B (en) Improvements in the treatment of animal feeds
RU1833740C (en) Way of treatment and prophylaxis of allergic diseases of reagent type
RU1785692C (en) Preparation for treatment and prophylaxis piglets colibacteriosis
RU1833739C (en) Way of treatment hyperekaliemia
ZA903993B (en) Treatment of animals
LTIP472A (en) Composition for the treatment of infection and disease caused by hepatit b virus
GB9013938D0 (en) Vaccine and treatment for the prevention of type i or juvenile diabetes